NiKem Research Srl Enters into Research Service Agreement with InterMune
News Jun 25, 2007
NiKem Research Srl has announced that it has entered into a Research Service Agreement with InterMune, Inc., a California-based biotechnology company focused on developing and commercializing innovative therapies in hepatology and pulmonology.
Under the terms of the agreement, NiKem will, in the next 12 months, use its medicinal chemistry and early ADMET/PK platform and expertise to design, synthesize and profile drug-like compounds aimed towards specific, undisclosed pulmonology targets of interest for InterMune. Financial terms of the agreement were not disclosed.
By pursuing this business opportunity with InterMune, NiKem Research further diversifies its client portfolio in Europe, the United States and Australia, now comprising large pharmaceutical corporations, small biotechs and a number of medium-sized companies.
Giuseppe Giardina, CEO of NiKem Research, said "Our integrated drug discovery platform will be applied to important projects within InterMune’s pulmonology research portfolio. We believe that our goal-oriented attitude, our teamwork-driven working approach and our pragmatic way of thinking will be of great value in this collaboration. Having noticed a similar mindset at InterMune since the start of our discussions, we’re very pleased to initiate this relationship among two leading companies in their respective areas.”
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE